<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917735</url>
  </required_header>
  <id_info>
    <org_study_id>0806M36121</org_study_id>
    <secondary_id>R01CA127236</secondary_id>
    <nct_id>NCT00917735</nct_id>
  </id_info>
  <brief_title>Green Tea and Reduction of Breast Cancer Risk</brief_title>
  <official_title>Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Green tea extract contains ingredients (catechins) that may lower the risk of
      breast cancer.

      PURPOSE: This phase II trial is studying how well green tea extract works in preventing
      breast cancer compared to a placebo in postmenopausal women with high breast density.

      The investigators have hypothesized that green tea consumption reduces breast cancer risk,
      and this effect is seen primarily in women who have the low-activity COMT genotype. The
      investigators will test this by evaluating the effects of green tea extract on breast cancer
      biomarkers including mammographic density, plasma insulin-like growth factor 1 (IGF-1), IGF
      binding protein 3 (IGFBP-3), estrone, estradiol, androstenedione, sex hormone binding
      globulin (SHBG), urinary estrogen metabolites and plasma F2-isoprostanes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        1. Primary:

           1.1 To determine the effects of green tea extract consumption (containing 800 mg EGCG
           per day) for 12 months on the following recognized biomarkers of breast cancer risk:

             1. Mammographic density

             2. Circulating concentrations of insulin-like growth factor 1 (IGF-1) and IGF binding
                protein 3 (IGFBP-3)

             3. Circulating concentrations of reproductive hormones (estrone, estradiol,
                androstenedione) and sex hormone binding globulin (SHBG)

           1.2 To determine the effects of COMT genotype on the green tea extract effects described
           above.

        2. Secondary:

      2.1 To determine the effects of green tea extract consumption (containing 800 mg EGCG per
      day) for 12 months on the following hypothesized biomarkers of breast cancer risk:

        1. Urinary estrogen metabolites (estrone, estradiol, and their 2-hydroxy, 4-hydroxy,
           2-methoxy, and 4-methoxy metabolites, estriol, and 16- hydroxyestrone)

        2. Circulating concentrations of F-2 isoprostanes, a recognized biomarker of systemic
           oxidative stress

      2.2 To determine the effects of COMT genotype on the green tea extract effects described
      above.

      2.3 To determine the effects of COMT genotype on catechin metabolism and excretion, as
      measured by circulating and urinary concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mammographic Density</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Percent mammographic density was measured on digital images using a computer-assisted and quantitative method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating Concentrations of Reproductive Hormones Including Estrone, Estradiol, Androstenedione, Testosterone, and Sex Hormone Binding Globulin (SHBG)</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Circulating levels of reproductive hormones including estrone, estradiol, androstenedione, testosterone and SHBG were measured in fasting blood samples by liquid chromatography/tandem mass spectrometry method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating Concentrations of IGF Axis Proteins Including IGF-1 and IGFBP-3</measure>
    <time_frame>Baseline and month 12</time_frame>
    <description>Circulating levels of IGF-1 and IGFBP-3 were measured in fasting blood samples by ELISA method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1075</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Green tea extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Green tea extract supplement</intervention_name>
    <description>Two green tea extract capsules twice daily after breakfast and dinner for one year</description>
    <arm_group_label>Green tea extract</arm_group_label>
    <other_name>Green tea extract: Corban green tea blend (GTB-3D)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two placebo capsules twice daily after breakfast and dinner for one year</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Healthy postmenopausal women aged 50-70 years

          -  &quot;Heterogeneously dense&quot; (51-75% glandular) or &quot;extremely dense&quot; (&gt;75%glandular)
             breasts

          -  Willing to avoid consumption of green tea for 1 year

        Exclusion Criteria:

          -  Positive serological markers of hepatitis B or hepatitis C infections

          -  Elevated levels of liver enzymes

          -  Recent (within 6 mo) or current hormone or hormone modification therapy, including
             systemic hormone replacement therapy, SERMS and aromatase inhibitors

          -  Current smoker of cigarettes or other tobacco products

          -  BMI &lt;19 or &gt;40 kg/m2

          -  Weight change &gt; 10 lbs during the previous year

          -  History of breast cancer or proliferative breast disease

          -  Regular consumption of &gt; 7 alcoholic drinks/wk

          -  Regular consumption of green tea (&gt;1 cup/wk)

          -  Recent (within 6 mo) or current use of chemopreventive agents such as tamoxifen,
             raloxifene or aromatase inhibitors

          -  Participation in any weight loss or weight gain studies

          -  Currently taking Methotrexate or Enbrel

          -  History of ovarian cancer

          -  Any form of cancer in the last 5 years

          -  Presence of implants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindy S Kurzer, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview Southdale Breast Center</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Maple Grove Breast Center</name>
      <address>
        <city>Maple Grove</city>
        <state>Minnesota</state>
        <zip>55369</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical Center (UMMC) Breast Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Institute</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Food Science and Nutrition, University of Minnesota</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26206423</url>
    <description>The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26051348</url>
    <description>The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>January 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Green tea</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Prevention</keyword>
  <keyword>COMT genotype</keyword>
  <keyword>EGCG (Epigallocatechin gallate)</keyword>
  <keyword>Mammographic density</keyword>
  <keyword>Reproductive hormones</keyword>
  <keyword>IGF axis proteins</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>August 2009 through April 2013</recruitment_details>
      <pre_assignment_details>Prior to randomization, participants went through a screening clinic visit in which anthropometric characteristics and blood pressure were measured. In addition, blood was drawn to assess catechol-O-methyltransferase (COMT) genotype, hepatic function, and serological markers of hepatitis B and C virus.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Green Tea Extract</title>
          <description>Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of epigallocatechin gallate (EGCG).</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="538"/>
                <participants group_id="P2" count="537"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
                <participants group_id="P2" count="474"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Green Tea Extract</title>
          <description>Green tea extract supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="538"/>
            <count group_id="B2" value="537"/>
            <count group_id="B3" value="1075"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="5.0"/>
                    <measurement group_id="B2" value="59.6" spread="5.1"/>
                    <measurement group_id="B3" value="59.8" spread="5.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="537"/>
                    <measurement group_id="B3" value="1075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="510"/>
                    <measurement group_id="B3" value="1026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="515"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538"/>
                    <measurement group_id="B2" value="537"/>
                    <measurement group_id="B3" value="1075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.5" spread="6.3"/>
                    <measurement group_id="B2" value="164.3" spread="6.2"/>
                    <measurement group_id="B3" value="163.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" spread="10.6"/>
                    <measurement group_id="B2" value="67.9" spread="10.5"/>
                    <measurement group_id="B3" value="67.4" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist-to-hip ratio</title>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.84" spread="0.1"/>
                    <measurement group_id="B2" value="0.83" spread="0.1"/>
                    <measurement group_id="B3" value="0.83" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mammographic Density</title>
        <description>Percent mammographic density was measured on digital images using a computer-assisted and quantitative method.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Mammographic density at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea Extract</title>
            <description>Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of EGCG.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.</description>
          </group>
        </group_list>
        <measure>
          <title>Mammographic Density</title>
          <description>Percent mammographic density was measured on digital images using a computer-assisted and quantitative method.</description>
          <population>Mammographic density at baseline and month 12</population>
          <units>Percent</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="470"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent mammographic density at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.71" lower_limit="21.39" upper_limit="24.10"/>
                    <measurement group_id="O2" value="21.84" lower_limit="20.59" upper_limit="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent mammographic density at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.09" lower_limit="20.77" upper_limit="23.50"/>
                    <measurement group_id="O2" value="21.13" lower_limit="19.88" upper_limit="22.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Circulating Concentrations of Reproductive Hormones Including Estrone, Estradiol, Androstenedione, Testosterone, and Sex Hormone Binding Globulin (SHBG)</title>
        <description>Circulating levels of reproductive hormones including estrone, estradiol, androstenedione, testosterone and SHBG were measured in fasting blood samples by liquid chromatography/tandem mass spectrometry method.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Circulating concentrations of reproductive hormones including estrone, estradiol, androstenedione, testosterone, sex hormone binding globulin (SHBG) at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea Extract</title>
            <description>Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of EGCG.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Concentrations of Reproductive Hormones Including Estrone, Estradiol, Androstenedione, Testosterone, and Sex Hormone Binding Globulin (SHBG)</title>
          <description>Circulating levels of reproductive hormones including estrone, estradiol, androstenedione, testosterone and SHBG were measured in fasting blood samples by liquid chromatography/tandem mass spectrometry method.</description>
          <population>Circulating concentrations of reproductive hormones including estrone, estradiol, androstenedione, testosterone, sex hormone binding globulin (SHBG) at baseline and month 12</population>
          <units>pg/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="463"/>
                <count group_id="O2" value="474"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Circulating estrone at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" lower_limit="21.6" upper_limit="24.0"/>
                    <measurement group_id="O2" value="23.6" lower_limit="22.4" upper_limit="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating estrone at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="21.3" upper_limit="23.7"/>
                    <measurement group_id="O2" value="22.4" lower_limit="21.3" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating estradiol at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.1" upper_limit="3.8"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.3" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating estradiol at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.4" upper_limit="4.1"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.8" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating androstenedione at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479.8" lower_limit="459.4" upper_limit="501.2"/>
                    <measurement group_id="O2" value="507.2" lower_limit="485.9" upper_limit="529.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating androstenedione at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468.8" lower_limit="450.2" upper_limit="488.3"/>
                    <measurement group_id="O2" value="479.5" lower_limit="460.6" upper_limit="499.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating testosterone at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.0" lower_limit="142.7" upper_limit="159.7"/>
                    <measurement group_id="O2" value="161.6" lower_limit="152.8" upper_limit="170.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating testosterone at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.1" lower_limit="149.9" upper_limit="166.9"/>
                    <measurement group_id="O2" value="155.1" lower_limit="147.1" upper_limit="163.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating SHBG at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="65.0" upper_limit="71.3"/>
                    <measurement group_id="O2" value="69.1" lower_limit="66.0" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating SHBG at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.7" lower_limit="65.5" upper_limit="72.0"/>
                    <measurement group_id="O2" value="68.7" lower_limit="65.5" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Circulating Concentrations of IGF Axis Proteins Including IGF-1 and IGFBP-3</title>
        <description>Circulating levels of IGF-1 and IGFBP-3 were measured in fasting blood samples by ELISA method.</description>
        <time_frame>Baseline and month 12</time_frame>
        <population>Circulating concentrations of IGF axis proteins including insulin-like growth factor (IGF-1) and IGF binding protein 3 (IGFBP-3) at baseline and month 12</population>
        <group_list>
          <group group_id="O1">
            <title>Green Tea Extract</title>
            <description>Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of EGCG.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.</description>
          </group>
        </group_list>
        <measure>
          <title>Circulating Concentrations of IGF Axis Proteins Including IGF-1 and IGFBP-3</title>
          <description>Circulating levels of IGF-1 and IGFBP-3 were measured in fasting blood samples by ELISA method.</description>
          <population>Circulating concentrations of IGF axis proteins including insulin-like growth factor (IGF-1) and IGF binding protein 3 (IGFBP-3) at baseline and month 12</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="473"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Circulating IGF-1 at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="85.3" upper_limit="89.8"/>
                    <measurement group_id="O2" value="88.3" lower_limit="86.1" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating IGF-1 at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" lower_limit="81.6" upper_limit="85.8"/>
                    <measurement group_id="O2" value="83.1" lower_limit="81.0" upper_limit="85.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating IGFBP-3 at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2048.0" lower_limit="2008.9" upper_limit="2088.0"/>
                    <measurement group_id="O2" value="2047.6" lower_limit="2008.9" upper_limit="2087.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Circulating IGFBP-3 at month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2048.1" lower_limit="2008.0" upper_limit="2089.1"/>
                    <measurement group_id="O2" value="2040.7" lower_limit="2001.0" upper_limit="2081.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>Adverse event information was coded and graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.</desc>
      <group_list>
        <group group_id="E1">
          <title>Green Tea Extract</title>
          <description>Green tea extract (GTE) supplement: Two green tea extract capsules twice daily after breakfast and dinner for one year. GTE was a decaffeinated green tea extract, and each capsule contained a total of 328.8 ± 28.9 mg catechins including 210.7 ± 11.0 mg of EGCG.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Placebo: Two placebo capsules twice daily after breakfast and dinner for one year. Placebo capsules contained maltodextrin, cellulose, and magnesium stearate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic Neuroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT or AST enzyme</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="538"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Diagnosis of Uterine Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Motorcycle accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="538"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="538"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="407" subjects_at_risk="538"/>
                <counts group_id="E2" subjects_affected="391" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="235" subjects_affected="235" subjects_at_risk="538"/>
                <counts group_id="E2" events="184" subjects_affected="184" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="538"/>
                <counts group_id="E2" events="77" subjects_affected="77" subjects_at_risk="537"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="280" subjects_affected="280" subjects_at_risk="538"/>
                <counts group_id="E2" events="218" subjects_affected="218" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="216" subjects_affected="216" subjects_at_risk="538"/>
                <counts group_id="E2" events="217" subjects_affected="217" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musuclar</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="538"/>
                <counts group_id="E2" events="69" subjects_affected="69" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respitory</sub_title>
                <counts group_id="E1" events="122" subjects_affected="122" subjects_at_risk="538"/>
                <counts group_id="E2" events="122" subjects_affected="122" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="154" subjects_affected="154" subjects_at_risk="538"/>
                <counts group_id="E2" events="144" subjects_affected="144" subjects_at_risk="537"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We had limited success in recruiting minority populations.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mindy Kurzer</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-9789</phone>
      <email>mkurzer@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

